ClinicalTrials.gg
Enrolling by invitationNCT06101940C-DMCOS-DM1Updated Jun 2, 2026

Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)

An observational study in Myotonic Dystrophy 1, sponsored by Huashan Hospital. Enrolling by invitation at 22 sites in China. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Huashan Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Study summary

Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disorder caused by an expanded CTG trinucleotide repeat in the 3' untranslated region of the DMPK gene. Beyond myotonia and progressive skeletal muscle weakness, DM1 involves the cardiac, respiratory, central nervous, gastrointestinal, endocrine, and ocular systems, and respiratory and cardiac involvement are the leading causes of disability and death. Systematic, long-term outcome data in Chinese DM1 patients are lacking.

C-DMCOS-DM1 is a multicenter, prospective, observational cohort study that systematically records demographic data, multisystem involvement, and predefined disability-related clinical outcome events in genetically confirmed Chinese DM1 patients, with regular follow-up every 3 to 6 months. The study also collects residual blood, skeletal muscle, myocardium (when a pacemaker is implanted), and urine specimens for transcriptomic and other molecular studies. The aims are to characterize the disease burden of Chinese DM1 patients, identify risk and prognostic factors for disabling outcomes, and build risk-prediction models to inform follow-up, management, and future clinical trials.

Read the detailed description

This multicenter, prospective, observational cohort study (no randomization, no control, no intervention) enrolls genetically confirmed DM1 patients across Chinese neuromuscular centers and follows them every 3 to 6 months. At baseline and each visit, the study collects demographics, clinical subtype, symptoms and rating scales, manual muscle testing and the Muscular Impairment Rating Scale (MIRS), quantitative motor measures (grip strength, 10-Metre Walk Test [10MWT], Video Hand Opening Time [vHOT]), cardiac assessment (electrocardiography and 24-hour Holter), pulmonary function testing, echocardiography, laboratory tests, computerized cognitive assessment, and video and voice recordings of gait, hand grip, and facial movement for artificial-intelligence analysis. Wearable devices are encouraged for continuous monitoring of heart rate and heart rate variability, blood oxygen saturation, respiratory rate, sleep and nocturnal respiratory events, and daily physical activity.

Predefined disability-related outcome events are tracked cumulatively, including loss of independent ambulation, respiratory failure, non-invasive or invasive mechanical ventilation, tracheostomy, cardiac pacemaker or implantable cardioverter-defibrillator (ICD) implantation, early cataract surgery, malignancy, and death. Residual blood, skeletal muscle, myocardium (when a pacemaker is implanted), and urine specimens are collected for RNA sequencing, mitochondrial DNA analysis, and other molecular studies. Statistical analysis includes descriptive characterization, Kaplan-Meier and Cox proportional-hazards survival analysis, competing-risk models, and multivariable regression to identify risk and prognostic factors and to build risk-prediction models.

02

Conditions studied

  • Myotonic Dystrophy 1

Browse trials for

Keywords

  • Observational
  • DMPK
  • clinical outcomes
  • multi-system involvement
03

In context

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.

Browse Myotonic Dystrophy studies →

Lead sponsor

Huashan Hospital is the lead sponsor of 248 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The patients will be diagnosed and invited to join this trial in each participating neuromuscular diagnostic centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Genetically confirmed DM1 (CTG repeat expansion in the 3' untranslated region of the DMPK gene).
  2. Any sex.
  3. Able to attend regular follow-up and willing to provide and store residual blood, urine, and other biospecimens for research.
  4. Voluntary participation with signed (signed by legal guardian for minors).
  5. Consent to use of routine clinical, examination, and follow-up data for research.

Exclusion criteria

Exclusion Criteria:

  1. Unable to comply with study procedures.
  2. Unable to provide , or guardian declines participation.
  3. Pregnancy (for MRI safety).
  4. Severe, unstable medical condition that precludes assessments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • DM1 patients

    Patient cohort

    Diagnostic Test: MRI scan · Diagnostic Test: Electrocardiography · Diagnostic Test: Pulmonary function test · Diagnostic Test: Electrocardiography and 24-hour Holter monitoring · Procedure: Skeletal muscle biopsy (residual specimen) · Device: Wearable-device continuous physiological monitoring · Behavioral: Video and voice recording for AI analysis

Interventions

  • Diagnostic testMRI scan

    Brain MRI scan to evaluate the integrity of the nervous system; lower limb muscle MRI scan to evaluate fat infiltration in skeletal muscles of the lower limb

  • Diagnostic testElectrocardiography

    Standard 12-lead electrocardiography or Holter monitoring performed to assess cardiac conduction abnormalities and arrhythmias in patients with DM1.

  • Diagnostic testPulmonary function test

    Comprehensive pulmonary function testing including spirometry to assess respiratory muscle weakness and restrictive lung disease in DM1 patients.

  • Diagnostic testElectrocardiography and 24-hour Holter monitoring

    Electrocardiography and 24-hour Holter monitoring

  • ProcedureSkeletal muscle biopsy (residual specimen)

    Skeletal muscle biopsy (residual specimen)

  • DeviceWearable-device continuous physiological monitoring

    Wearable-device continuous physiological monitoring (heart rate, blood oxygen saturation, respiration, physical activity, sleep)

  • BehavioralVideo and voice recording for AI analysis

    Video and voice recording for AI analysis (gait, hand grip, facial movement, speech)

06

What researchers measure

Primary outcomes

  1. Cumulative incidence and time to first major disability-related clinical outcome event

    Proportion of participants experiencing, and time to first occurrence of, predefined disability-related outcome events: loss of independent ambulation, respiratory failure, non-invasive mechanical ventilation, invasive mechanical ventilation, tracheostomy, cardiac pacemaker implantation, implantable cardioverter-defibrillator (ICD) implantation, early cataract surgery, malignancy, and death. Each event is recorded with its date of first occurrence.

    Time frame: From enrollment up to 10 years

Secondary outcomes

  1. Change in 10-Metre Walk Test (10MWT)

    Time in seconds to walk 10 metres, assessing functional mobility.

    Time frame: Baseline, Year 1, Year 3, Year 5, Year 10

  2. Change in Video Hand Opening Time (vHOT)

    Time to fully open the hand after making a fist, an objective measure of myotonia severity.

    Time frame: Baseline, Year 1, Year 3, Year 5, Year 10

  3. Change in Muscular Impairment Rating Scale (MIRS)

    Five-point clinical rating of muscle impairment in DM1.

    Time frame: Baseline, Year 1, Year 3, Year 5, Year 10

  4. Change in forced vital capacity (FVC, % predicted)

    Pulmonary function measure reflecting respiratory involvement.

    Time frame: Baseline, Year 1, Year 3, Year 5, Year 10

  5. Change in Epworth Sleepiness Scale (ESS)

    0 to 24 scale of daytime sleepiness; higher scores indicate greater sleepiness.

    Time frame: Baseline, Year 1, Year 3, Year 5, Year 10

  6. Change in Fatigue Severity Scale (FSS)

    9-item fatigue scale; higher scores indicate more severe fatigue.

    Time frame: Baseline, Year 1, Year 3, Year 5, Year 10

07

Study locations

22 sites
08

References and documents

Publications

  • Zhong H, Zeng L, Yu X, Ke Q, Dong J, Chen Y, Luo L, Chang X, Guo J, Wang Y, Xiong H, Liu R, Liu C, Wu J, Lin J, Xi J, Zhu W, Tan S, Liu F, Lu J, Zhao C, Luo S. Clinical features and genetic spectrum of a multicenter Chinese cohort with myotonic dystrophy type 1. Orphanet J Rare Dis. 2024 Mar 7;19(1):103. doi: 10.1186/s13023-024-03114-z. PubMed 38454488 ↗

Related links

Individual participant data

Plan to share: No — Individual participant data will not be shared publicly. The data are subject to China's Regulations on the Administration of Human Genetic Resources. All participant data are managed anonymously and identified by study number rather than name, and are accessible only to authorized study personnel.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Aug 2030, 108 months after the start.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 108 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Oct 26, 2023
StartActual
Aug 1, 2021
Primary completionEst.
Aug 1, 2030
CompletionEst.
Dec 30, 2035
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06101940
Lead sponsor
Huashan Hospital
Responsible party
Chongbo Zhao (Professor, Huashan Hospital) — Principal investigator
First posted
Oct 26, 2023
Start date
Aug 1, 2021
Primary completion
Aug 1, 2030 (estimated)
Completion
Dec 30, 2035 (estimated)
Last update
Jun 2, 2026

Study contacts

Chongbo Zhao, PhD
study director · Huashan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion